Related Experiment Video
Updated: Jun 30, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
Acquired Reactive Perforating Collagenosis Treated with Upadacitinib: A Case Report and Literature Review
Bo Xie1, Xiaoyan Zhang1, Xinxin Lei1
1Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310009, People's Republic of China.
None:
Acquired reactive perforating collagenosis (ARPC) is a rare perforating dermatosis linked to systemic diseases, with unclear pathogenesis and no standardized therapy. We report a 53-year-old male with ARPC who failed conventional treatments but improved rapidly with upadacitinib 15 mg/day for one month, followed by 15 mg every other day. After three months, most lesions resolved, leaving hyperpigmentation and scars. Literature review shows conflicting reports: one case of ARPC improved with upadacitinib, another developed ARPC during upadacitinib treatment for atopic dermatitis. Our findings suggest upadacitinib may be effective for ARPC, especially in pruritic patients, regardless of diabetes status.
Related Concept Videos
The JAK-STAT Signaling Pathway
Chronic Pancreatitis II: Collaborative Care
Assessment:
Pericarditis I: Introduction
Pericarditis III: Medical Management

